Novel BRCA2-interacting protein BJ-HCC-20A inhibits the induction of apoptosis in response to DNA damage

Cancer Science

Volumn 99, Issue 4, 2008, Pages 747-754

  Tomiyoshi, Go ^a   Nakanishi, Akira ^b   Takenaka, Katsuya ^a   Yoshida, Kiyotsugu ^a   Miki, Yoshio ^a,b  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b CANCER INSTITUTE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA2 PROTEIN; DOXORUBICIN; PROTEIN BJ HCC 20A; REGULATOR PROTEIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANIMAL CELL; APOPTOSIS; ARTICLE; CARCINOGENESIS; CELL CYCLE REGULATION; CENTROSOME; CYTOKINESIS; DNA DAMAGE; DNA REPAIR; GENE OVEREXPRESSION; GENOMIC INSTABILITY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MOUSE; NONHUMAN; PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; RECEPTOR DOWN REGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TWO HYBRID SYSTEM;

AMINO ACID SEQUENCE; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BRCA2 PROTEIN; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; CONSERVED SEQUENCE; DNA DAMAGE; DOWN-REGULATION; DOXORUBICIN; HUMANS; MICE; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; RNA, MESSENGER; RNA, SMALL INTERFERING; TWO-HYBRID SYSTEM TECHNIQUES;

EID: 41349107797     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2008.00733.x     Document Type: Article

References (38)

1. Stratton MR, Wooster R. Hereditary predisposition to breast cancer. Curr Opin Genet Dev 1996; 6: 93-7.
2. Miki Y, Swensen J, Shattuck-Eidens D et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994; 266: 66-71.
3. Wooster R, Bignell G, Lancaster J et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995; 378: 789-92.
4. Tavtigian SV, Simard J, Rommens J et al. The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds. Nat Genet 1996; 12: 333-7.
5. Gudmundsson J, Johannesdottir G, Bergthorsson JT et al. Different tumor types from BRCA2 carriers show wild-type chromosome deletions on 13q12-q13. Cancer Res 1995; 55: 4830-2.
6. Sharan SK, Morimatsu M, Albrecht U et al. Embryonic lethality and radiation hypersensitivity mediated by Rad51 in mice lacking Brca2. Nature 1997; 386: 804-10.
7. Patel KJ, Yu VP, Lee H et al. Involvement of Brca2 in DNA repair. Mol Cell 1998; 1: 347-57.
8. Tutt A, Bertwistle D, Valentine J et al. Mutation in Brca2 stimulates error-prone homology-directed repair of DNA double-strand breaks occurring between repeated sequences. EMBO J 2001; 20: 4704-16.
9. Yuan SS, Lee SY, Chen G, Song M, Tomlinson GE, Lee EY. BRCA2 is required for ionizing radiation-induced assembly of Rad51 complex in.vivo. Cancer Res 1999; 59: 3547-51.
10. Esashi F, Christ N, Gannon J et al. CDK-dependent phosphorylation of BRCA2 as a regulatory mechanism for recombinational repair. Nature 2005; 434: 598-604.
11. Milner J, Ponder B, Hughes-Davies L, Seltmann M, Kouzarides T. Transcriptional activation functions in BRCA2. Nature 1997; 386: 761-3.
12. Marmorstein LY, Ouchi T, Aaronson SA. The BRCA2 gene product functionally interacts with p53 and RAD51. Proc Natl Acad Sci USA 1998; 95: 13.869-74.
13. Hughes-Davies L, Huntsman D, Ruas M et al. EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer. Cell 2003; 115: 523-35.
14. Vaughn JP, Cirisano FD, Huper G et al. Cell cycle control of BRCA2. Cancer Res 1996; 56: 4590-4.
15. 2/M checkpoint control. J Biol Chem 1999; 274: 32.931-5.
16. Marmorstein LY, Kinev AV, Chan GK et al. A human BRCA2 complex containing a structural DNA binding component influences cell cycle progression. Cell 2001; 104: 247-57.
17. Wang SC, Shao R, Pao AY, Zhang S, Hung MC, Su LK. Inhibition of cancer cell growth by BRCA2. Cancer Res 2002; 62: 1311-14.
18. Tian XX, Rai D, Li J et al. BRCA2 suppresses cell proliferation via stabilizing MAGE-D1. Cancer Res 2005; 65: 4747-53.
19. Gretarsdottir S, Thorlacius S, Valgardsdottir R et al. BRCA2 and p53 mutations in primary breast cancer in relation to genetic instability. Cancer Res 1998; 58: 859-62.
20. Tutt A, Gabriel A, Bertwistle D et al. Absence of Brca2 causes genome instability by chromosome breakage and loss associated with centrosome amplification. Curr Biol 1999; 9: 1107-10.
21. Gudmundsdottir K, Ashworth A. The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability. Oncogene 2006; 25: 5864-74.
22. Cheung AM, Hande MP, Jalali F et al. Loss of Brca2 and p53 synergistically promotes genomic instability and deregulation of T-cell apoptosis. Cancer Res 2002; 62: 6194-204.
23. Nakanishi A, Han X, Saito H et al. Interference with BRCA2, which localizes to the centrosome during S and early M phase, leads to abnormal nuclear division. Biochem Biophys Res Commun 2007; 355: 34-40.
24. Daniels MJ, Wang Y, Lee M, Venkitaraman AR. Abnormal cytokinesis in cells deficient in the breast cancer susceptibility protein BRCA2. Science 2004; 306: 876-9.
25. Lin HR, Ting NS, Qin J, Lee WH. M phase-specific phosphorylation of BRCA2 by Polo-like kinase 1 correlates with the dissociation of the BRCA2-P/CAF complex. J Biol Chem 2003; 278: 35.979-87.
26. Lee M, Daniels MJ, Venkitaraman AR. Phosphorylation of BRCA2 by the Polo-like kinase Plk1 is regulated by DNA damage and mitotic progression. Oncogene 2004; 23: 865-72.
27. Lu H, Guo X, Meng X et.al. The BRCA2-interacting protein BCCIP functions in RAD51 and BRCA2 focus formation and homologous recombinational repair. Mol Cell Biol 2005; 25: 1949-57.
28. Dong XY, Li YY, Yang XA, Chen WF. BJ-HCC-20, a potential novel cancer-testis antigen. Biochem Cell Biol 2004; 82: 577-82.
29. Park JH, Lin ML, Nishidate T, Nakamura Y, Katagiri T. PDZ-binding kinase/ T-LAK cell-originated protein kinase, a putative cancer/testis antigen with an oncogenic activity in breast cancer. Cancer Res 2006; 66: 9186-95.
30. Andres JL, Fan S, Turkel GJ et al. Regulation of BRCA1 and BRCA2 expression in human breast cancer cells by DNA-damaging agents. Oncogene 1998; 16: 2229-41.
31. Hay T, Patrick T, Winton D, Sansom OJ, Clarke AR. Brca2 deficiency in the murine small intestine sensitizes to p53-dependent apoptosis and leads to the spontaneous deletion of stem cells. Oncogene 2005; 24: 3842-6.
32. Fan S, Twu NF, Wang JA et al. Down-regulation of BRCA1 and BRCA2 in human ovarian cancer cells exposed to adriamycin and ultraviolet radiation. Int J Cancer 1998; 77: 600-9.
33. Yuan R, Fan S, Wang JA et al. Coordinate alterations in the expression of BRCA1, BRCA2, p300, and Rad51 in response to genotoxic and other stresses in human prostate cancer cells. Prostate 1999; 40: 37-49.
34. Su J, Ciftci K. Changes in BRCA1 and BRCA2 expression produced by chemotherapeutic agents in human breast cancer cells. Int J Biochem Cell Biol 2002; 34: 950-7.
35. Wu K, Jiang SW, Couch FJ. p53 mediates repression of the BRCA2 promoter and down-regulation of BRCA2 mRNA and protein levels in response to DNA damage. J Biol Chem 2003; 278: 15.652-60.
36. Simpson AJ, Caballero OL, Jungbluth A, Chen YT, Old LJ. Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer 2005; 5: 615-25.
37. Mischo A, Kubuschok B, Ertan K et al. Prospective study on the expression of cancer testis genes and antibody responses in 100 consecutive patients with primary breast cancer. Int J Cancer 2006; 118: 696-703.
38. Chen X, Arciero CA, Wang C, Broccoli D, Godwin AK. BRCC36 is essential for ionizing radiation-induced BRCA1 phosphorylation and nuclear foci formation. Cancer Res 2006; 66: 5039-46.